Jazz buys Priority Review voucher from Spark

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) purchased a rare pediatric disease Priority Review voucher from Spark Therapeutics Inc. (NASDAQ:ONCE) for $110 million.

Jazz spokesperson Andrew Civers-Davis told BioCentury the company has not yet decided how to use the voucher. The biotech's late-stage pipeline includes Phase III narcolepsy candidate JZP-258. In March, the company said it will submit an NDA next year for the oral solution containing a mixture of oxybate salts...